Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for Behavioral Symptoms in Dementia
NCT00249158Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 1998
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in Dementia, Alzheimer's disease (AD), vascular dementia, sponsored by Janssen Pharmaceutical. Started Mar 1998; status: completed.
02
Drugs
risperidone
03
Conditions
DementiaAlzheimer's disease (AD)vascular dementia
Beyond the preview
Go deeper on NCT00249158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249158.